Annual Meeting Proceedings, Part 1

activity adjuvant adverse events analysis assessed associated Background baseline bevacizumab breast cancer Cancer Center Cancer Institute capecitabine carcinoma cells cetuximab chemotherapy cisplatin clinical trial cohort colorectal cancer combination Conclusions correlated cycles diagnosis diarrhea docetaxel dose levels ECOG efficacy EGFR enrolled erlotinib evaluated factors FOLFIRI gemcitabine gene grade hazard ratio HER2 included inhibitor irinotecan KRAS lapatinib mCRC median age Medical Center metastatic metastatic breast cancer Methods mg/kg mg/m² months neoadjuvant neutropenia Oncology oral outcome overall survival oxaliplatin paclitaxel pancreatic patients pts pharmacokinetics phase II study phase II trial Poster Discussion Poster Session Board predictive primary endpoint prior prognostic progression prostate cancer pts received randomized range receptor recurrence regimen respectively response rate Results risk safety significant significantly solid tumors sorafenib stable disease stage status sunitinib surgery taxane therapy tolerated toxicity trastuzumab treated treatment tumor vaccine VEGF weeks